Hepatitis B vaccine is effective in preventing infection with hepatitis B virus (HBV), but its duration of protection is unknown. To examine the effect of exposure to HBV on an immunized population, data were analyzed from a cohort of Alaska Natives who were immunized and then followed up annually for 10 years. A boost in antibody to hepatitis B surface antigen (anti-HBs) was defined as a fourfold rise in levels to §20 mIU/mL that was not accompanied by the presence of antibody to hepatitis B core antigen or attributable to interim vaccination. During 10 years of follow-up, 8.2% of 1,595 vaccinees had boosts in anti-HBs. Persons with boosts did not differ significantly from those without boosts in terms of age, gender, village, initial level of anti-HBs, or level of anti-HBs before the boost. These results underscore the continued exposure to HBV among vaccinees and the continued protection against disease that the vaccine provides.
Hepatitis B vaccine has been demonstrated to be effective Methods in preventing infection with hepatitis B virus (HBV) [1] , and
The recruitment, vaccination, and follow-up of this cohort widespread use of this vaccine has been recommended [2, 3] .
have been described in detail elsewhere [6, 9] . In brief, beginHowever, the question of how long protection will last remains ning in 1981, a group of 1,630 persons from 15 villages in unanswered and is the subject of extensive research, discussion, southwest Alaska received three doses each of plasma-derived and speculation [4, 5] . Attention has focused on the peak level hepatitis B vaccine (Heptavax, Merck, West Point, PA). Chilof antibody to hepatitis B surface antigen (anti-HBs) attained dren younger than 11 years of age received a 10-mg dose; all after vaccination, the duration after immunization that circulatother participants received a 20-mg dose. ing antibody can be detected, and whether detectable antibody Serum specimens were collected annually and tested for antiis necessary for protection from infection. One piece of this HBs (AUSAB, Abbott Laboratories, North Chicago, IL) and puzzle is the response of previously vaccinated individuals to antibody to hepatitis B core antigen (anti-HBc) (CORAB, Abexposure to HBV.
bott Laboratories) by RIA. Serum specimens positive for antiWe have previously reported on a project begun in 1981 to HBc were retested and if again positive were then tested for immunize a cohort of susceptible Alaska Natives living in a hepatitis B surface antigen (HBsAg) (AUSRIA II, Abbott Labregion where HBV infection is endemic [6 -9] . This group oratories). Serum specimens were redrawn from all study partiinitially consisted of 1,630 individuals of both genders and a cipants whose retests were positive for anti-HBc, and the secvariety of ages who were fully immunized with hepatitis B ond specimen was tested to confirm positivity for anti-HBc. vaccine and who have been followed up serologically for eviLevels of anti-HBs were measured in milli -international units; dence of disease annually for 10 years. We report evidence of measurements were calculated by using a World Health Orgaboosts in levels of anti-HBs that occurred in vaccinees during nization reference standard diluted to contain 125 mIU/mL. this 10-year period in response to possible exposure to HBV.
Testing was performed at the Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
Received 3 September 1997; revised 8 December 1997.
We defined a boost in anti-HBs as a fourfold or greater rise
Informed consent was obtained from all participants or their parents or guardians before entry into the study, and the protocol was approved by the in levels to at least 20 mIU/mL in two consecutive specimens local Native health boards.
£2 years apart that was not accompanied by the presence of requirement to achieve a level of at least 20 mIU/mL was made concurrent with the appearance of anti-HBc. Of the 177 participants with a fourfold rise not attributable to antibody to hepatiin proportions. Correlations were calculated by using Spearman's rank correlation. All P values were two-sided. Results tis B core antigen (anti-HBc) seroconversion or vaccination, 130 had a rise to a level of §20 mIU/mL after the boost. were considered to be statistically significant when P õ .05.
Omitting the participants who underwent seroconversion, the proportion of persons who had boosts in anti-HBs alone did Results not vary significantly by age, with boosts in 8.0% of those younger than 20 years of age at the first dose, 9.7% of those
Vaccination and Serological Responses During 10 Years
20 to 49 years of age, and 6.0% of those 50 years of age or Of the 1,630 participants who received the vaccine on schedolder (P Å .915). Likewise, the proportion did not vary by ule, 1,595 remained negative for anti-HBc during administragender, with 8.3% of males and 8.2% of females having a tion of the three doses of vaccine. At the time of administration boost (P Å .956). Residents of households that contained a of the first dose, the participants ranged in age from younger chronically HBsAg-infected person (10.4% of participants) than 1 year to 83 years. The mean age of the participants was tended to have more boosts in anti-HBs (11.0%) than did others 19.4 years, and the median age was 13 years. Seventy-five (7.9%), but this difference was not significant (RR Å 1.39; percent of the participants were younger than 26 years of age P Å .226). at that time. Males accounted for 49% of the cohort. Of those Proportions of boosts in anti-HBs by community of residence participants from whom serum specimens were obtained 1 year varied from a low of 5.0% to a high of 16.1%, but this differafter the first dose of vaccine, 94.1% (1,349 of 1,434) had an ence was not significant (P Å .722) (table 1). The proportion antibody response (level of anti-HBs, §10 mIU/mL).
of boosts in each village was positively associated with the Participation throughout the follow-up period was good:
proportion of villagers who were chronically infected with specimens were drawn from 1,194 (75%) of 1,595 persons at HBV, but this difference did not achieve statistical significance either 9 or 10 years after vaccination. Specimens were obtained (r s Å .423; P Å .116). from an additional 134 (8.4%) of 1,595 persons and were tested
The level of initial response to hepatitis B vaccine was also for evidence of HBV infection after the 10-year follow-up not a predictor of boosts in anti-HBs: 8.4% of persons who period. Eighty of the study participants died during the 10-year did not respond, 5.4% of those with an initial response between follow-up, representing an annual age-adjusted death rate of §10 mIU/mL and õ50 mIU/mL, and 8.9% of others had boosts 579 per 100,000 (less than the rate of 698 per 100,000 among (P Å .923). The level of anti-HBs in the specimen obtained all Alaska Natives) [10] . Seventeen additional participants have immediately before the boost varied from undetectable (12% died since the 10-year follow-up, all due to causes unrelated of individuals) to §1,000 mIU/mL (7%). The median level to HBV infection. Another 147 participants are known to have before the boost was 69.4 mIU/mL. The median level after the been alive at the end of the study period as documented by boost was 944 mIU/mL: 81% of persons had a level of §100 other health-related encounters. Twenty-five (1.6%) of 1,595 mIU/mL, and 48% had a level of §1,000 mIU/mL. original participants were totally lost to follow-up.
Boosts in anti-HBs occurred throughout the study period A total of 9,615 pairs of consecutive specimens were comfrom the first year to the ninth year of follow-up. When paired pared to look for potential boosts. These pairs represent an serum specimens were examined, the smallest proportion of average of 6.0 pairs per person. No paired specimens were boosts was seen in the first year after vaccination (0.7%), and available from 124 (7.8%) of 1,595 persons, while 74% (1,182 the largest proportion was seen in the fifth year (2.4%). There of 1,595) had five or more pairs and 53% (851 of 1,595) had tended to be more boosts later in the study (P Å .036; test for seven or more pairs. Approximately one-half (51%) of the pairs trend); a boost was shown in 1.8% of specimen pairs in the were from the 4 years immediately following blood sampling ninth year. at the 1-year follow-up, and the rest were from the subsequent Logistic regression analysis was used to examine the roles of 5 years of follow-up.
age, gender, initial response, village, presence of an individual chronically infected with HBV in the household, and anti-HBc seroconversion following boosts in anti-HBs. The only factor
Boosts in the Population
that was significantly associated with a boost in anti-HBs was anti-HBc seroconversion (P õ .001) (table 2). After adjustment Two hundred thirty-three individuals were identified who had a fourfold or greater increase in levels of anti-HBs between for anti-HBc seroconversion, no other factors were significant, although the presence of a person chronically infected with 1 and 10 years after administration of the first dose of vaccine. We found evidence that 52 persons who had had a fourfold HBV in the household showed a trend. If both boosts in anti-/ 9c4a$$ap28 03-10-98 11:48:05 cida UC: CID HBs and anti-HBc seroconversions were classified as HBV able to subsequent revaccination or anti-HBc seroconversion, a total of 130 persons (or 8.2% of 1,595 persons) had boosts events and treated as cases in the dependent variable, no significant associations were seen. follow-up; their definition required a level of anti-HBs of ú100 mIU/mL in children with levels of õ10 mIU/mL before the HBV infection who live in an area in which HBV is hyperendemic. Excluding rises in levels of anti-HBs that were attributboost and levels of anti-HBs of ú200 mIU/mL with a twofold NOTE. Persons with boosts attributable to interim vaccination and those for whom levels of anti-HBs were not measured at the initial follow-up were omitted from this analysis. anti-HBc Å antibody to hepatitis B core antigen; anti-HBs Å antibody to hepatitis B surface antigen; HBV Å hepatitis B virus.
/ 9c4a$$ap28
03-10-98 11:48:05 cida UC: CID increase in other children. Coursaget et al. [12] saw four sharp enrolled in the study became chronically infected with HBV during this period, nor were any cases of acute clinical hepatitis rises in antibody levels in 141 children 5 or 6 years after vaccination during infancy; these researchers' definition of a B detected in vaccinees. These results continue to support the view held by many researchers and public health experts [2, sharp rise was not clear. Lee et al. [13] found increases in 58 (11%) of 548 serum specimen pairs from 171 infants born to 16] that in populations with good coverage of hepatitis B vaccine and a good response to hepatitis B vaccination, protection mothers positive for hepatitis B e antigen over 5 years; they defined an increase as a fourfold rise. Hadler et al. [14] found persists for extended periods after the initial vaccine series. In populations for whom HBV is endemic, such as Alaska Nathat 3.5% of vaccinated homosexual men had a fourfold rise over 5 years of study. Our rate appears similar to or slightly tives, the duration of this protection may be enhanced by repeated exposure to HBV, resulting in periodic boosts in levels less than the rates in these studies, although our follow-up period was the longest and our cohort was the largest studied of anti-HBs. and included a variety of age groups and both genders. In addition, the exposure to natural infection in persons in our study was probably quite variable as village-specific rates of drawn and tested at approximately yearly intervals, the levels Thus, it appears that in this population of Alaska Natives, 
